RxDoctor Payments Data

Joel Phillips

Nurse Practitioner · Valparaiso, INNPI 1811654007

Payments from drug & device makers

$5,568in general payments, 2019–2025

Across 316 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$824
  • Johnson & Johnson$536
  • Madrigal Pharmaceuticals$382
  • Phathom Pharmaceuticals, Inc.$261
  • Sanofi$248
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,556100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,568 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$44,978
Medicare patients
398
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide81$71,341
CreonLipase/Protease/Amylase12$40,141
IbsrelaTenapanor Hcl12$30,397
MotegrityPrucalopride Succinate11$6,578
Dicyclomine Hcl177$5,302
Dexlansoprazole DrDexlansoprazole26$5,025
Colestipol Hcl22$3,126
Pantoprazole Sodium206$2,970
Esomeprazole Magnesium32$2,692
Cholestyramine LightCholestyramine14$2,505
Lubiprostone16$2,437
Omeprazole105$1,276
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine41$927
Ondansetron OdtOndansetron23$512
Balsalazide Disodium11$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,338$111,48293 claims
Ardelyx, Inc.Ibsrela$232$30,39712 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$824$6,57811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →